Anisha B. Patel, M.D.
Department of Dermatology, Division of Internal Medicine
Meet Anisha Patel, M.D.
Podcast: Sun safety advice for cancer survivors
In the News
Dermatologist: How to deal with targeted therapy-related skin rashes
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
Need a punch biopsy? Here’s what to expect
Cancer treatment-related nail changes: 7 things to know
9 sunscreen myths debunked
5 questions about laser tattoo removal, answered
Pregnancy-related skin changes or skin cancer? How to tell the difference
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Chief, Section of Cutaneous Toxicities, Department of Dermatology, Division of Division Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2008 | Baylor College of Medicine, Houston, TX, USA, MD, Doctor of Medicine |
| 2002 | Rice University, Houston, TX, USA, BS, Mechanical Engineering and Materials Science |
Postgraduate Training
| 2012-2013 | Clinical Fellowship, Dermatopathology, University of Texas-Medical Branch, Galveston, TX |
| 2009-2012 | Clinical Residency, Dermatology, Oregon Health and Science University, Portland, OR |
Experience & Service
Institutional Committee Activities
Member, Dermatology Chair Search Advisory Committee, 2023 - Present
Divisional Representative, PRS Faculty Compensation & Benefit Advisory Committee, Divisional Representative, 2023 - Present
Honors & Awards
| 2018 | Top 10% Nationally: Clinician and Group Consumer Assessment of Healthcare Providers and Systems 2018 |
Selected Publications
Peer-Reviewed Articles
- Seervai RNH, Heberton M, Cho WC, Gill P, Murphy MB, Aung PP, Nagarajan P, Torres-Cabala CA, Patel AB, Ruiz-Bañobre J, Om A, Yamamoto T, Nikolaou V, Curry JL. Severe De Novo pustular psoriasiform immune-related adverse event associated with Nivolumab treatment for metastatic esophageal adenocarcinoma. J Cutan Pathol 49(5):472-481, 2022. e-Pub 2021. PMID: 34888886.
- Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):JCO2101113, 2022. e-Pub 2021. PMID: 34550757.
- Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LE. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer 128(5):975-983, 2022. e-Pub 2021. PMID: 34724197.
- Ibraheim MK, Gupta R, Dao H, Patel AB, Koshelev M. Evaluating skin of color education in dermatology residency programs: data from a national survey: Edited by Stephen P. Stone, MD. Clin Dermatol 40(2):228-233, 2022. e-Pub 2021. PMID: 34838657.
- Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist 27(3):e223-e232, 2022. PMID: 35274723.
- Lo JJ, Heberton MM, Pacha O, Huen AO, Patel AB. Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients. Support Care Cancer 30(2):989-994, 2022. e-Pub 2021. PMID: 34519869.
- Robinson MA, Patel AB, Wilmas KM, Thomas V, Heberton M. Cutaneous Surgery Outcomes in Patients on Epidermal Growth Factor Receptor Inhibitors. Dermatol Surg 47(11):1519-1521, 2021. e-Pub 2021. PMID: 34417386.
- Karri PV, Tahseen D, Gupta R, Grant-Kels JM, Narala S, Patel AB. Can quality keep up with quantity-Longitudinal trends in research output for the dermatology residency match. Clin Dermatol 39(6):1039-1045, 2021. e-Pub 2021. PMID: 34920822.
- Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A. Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy. Cancer Discov 11(9):2158-2167, 2021. e-Pub 2021. PMID: 33910927.
- Altan M, Patel AB. Management of Cutaneous Immunotherapy Toxicities. Clin Lung Cancer 22(5):e783, 2021. e-Pub 2021. PMID: 33795210.
- Gupta R, Ibraheim MK, Dao H, Patel AB, Koshelev M. Assessing dermatology resident confidence in caring for patients with skin of color. Clin Dermatol 39(5):873-878, 2021. e-Pub 2021. PMID: 34785015.
- Brown AM, Masterson W, Lo J, Patel AB. Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review. Dermatitis. e-Pub 2021. PMID: 34405836.
- Barrios DM, Phillips GS, Geisler AN, Trelles SR, Markova A, Noor SJ, Quigley EA, Haliasos HC, Moy AP, Schram AM, Bromberg J, Funt SA, Voss MH, Drilon A, Hellmann MD, Comen EA, Narala S, Patel AB, Wetzel M, Jung JY, Leung DYM, Lacouture ME. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 32(6):736-745, 2021. e-Pub 2021. PMID: 33667669.
- Narala S, Li SQ, Klimas NK, Patel AB. Application of least absolute shrinkage and selection operator logistic regression for the histopathological comparison of chondrodermatitis nodularis helicis and hyperplastic actinic keratosis. J Cutan Pathol 48(6):739-744, 2021. e-Pub 2020. PMID: 33617003.
- Hanania HL, Pacha O, Heberton M, Patel AB. Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies. Dermatol Surg 47(6):775-779, 2021. PMID: 34029250.
- Keiser MF, Patel AB, Altan M. Cutaneous toxicities in lung cancer patients on immune checkpoint inhibitor therapy. Clin Lung Cancer 22(3):195-200.e1, 2021. e-Pub 2021. PMID: 33637416.
- McNally MA, Vangipuram R, Campbell MT, Nagarajan P, Patel AB, Curry JL, Heberton M. Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma. JAAD Case Rep 10:82-84, 2021. e-Pub 2021. PMID: 33778141.
- Karri PV, Tahseen D, Patel AB. Treatment of Checkpoint Inhibitor-Induced Vitiligo in a Patient with Metastatic Renal Cell Cancer. Dermatitis 32(4):e68-e69, 2021. e-Pub 2020. PMID: 33273227.
- Karri P, Freemyer B, Aboul-Fettouh N, Patel AB, Curry JL, Rogge M. Plasma cell myeloma with immature plasma cells in the skin arising within the areas of chronic stasis dermatitis. JAAD Case Rep 7:26-29, 2021. e-Pub 2020. PMID: 33318997.
Patient Reviews
CV information above last modified June 24, 2024